Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM5.07
|
Submission of Matters to a Vote of Security Holders |
On June 29, 2017,Kadmon Holdings, Inc. (the Company) held its
2017 Annual Meeting of Stockholders (the Annual Meeting), at
which a quorum was present. At the Annual Meeting, the
stockholders of the Company voted on the following three
proposals:
Proposal 1 Election of Directors
The following nominees were elected to the Companys Board of
Directors to hold office forterms to expire in one year oruntil
their successors are electedand qualified. The votes cast at the
Annual Meeting were as follows:
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Harlan W. Waksal, M.D. |
18,444,306 | 25,663 | 11,025,309 |
|
Bart M. Schwartz, Esq. |
18,445,988 | 23,981 | 11,025,309 |
|
Eugene Bauer, M.D. |
17,849,622 | 620,347 | 11,025,309 |
|
D. Dixon Boardman |
17,854,254 | 615,715 | 11,025,309 |
|
Alexandria Forbes, Ph.D. |
18,447,033 | 22,936 | 11,025,309 |
|
Tasos G. Konidaris |
18,446,079 | 23,890 | 11,025,309 |
|
Steven Meehan |
18,445,904 | 24,065 | 11,025,309 |
|
Thomas E. Shenk, Ph.D. |
18,445,865 | 24,104 | 11,025,309 |
|
Susan Wiviott, J.D. |
17,854,876 | 615,093 | 11,025,309 |
Proposal 2 Ratification of Appointment of Independent Registered
Public Accounting Firm
The proposal to ratify the appointment of BDO USA, LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017 was approved based upon the
following votes:
|
For |
Against |
Abstain |
| 29,411,848 | 47,595 | 35,835 |
Proposal 3 Vote to Approve Our Non-Employee Directors Equity
Compensation Policy
The proposal to approve the Companys Non-Employee Directors
Equity Compensation Policy was approved based upon the following
votes:
|
For |
Against |
Abstain |
Broker Non-Votes |
| 17,670,715 | 441,944 | 357,310 | 11,025,309 |
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.